Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6

References

• Saarikoski T, Saari TI, Hagelberg NM, et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol. 2015;71(3):321–327. doi:10.1007/s00228-014-1799-225560051
   PubMed Web of Science ®Google Scholar
• Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs. 1997;53(Suppl 2):18–24. doi:10.2165/00003495-199700532-000069190321
   PubMed Web of Science ®Google Scholar
• Faria J, Barbosa J, Moreira R, Queirós O, Carvalho F, Dinis‐Oliveira R. Comparative pharmacology and toxicology of tramadol and tapentadol. Eur J Pain. 2018;22(5):827–844. doi:10.1002/ejp.119629369473
   PubMed Web of Science ®Google Scholar
• Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol. 2015;53(6):545–550. doi:10.3109/15563650.2015.1036279
   PubMed Web of Science ®Google Scholar
• Mohammadpour A, Ashkezari MD, Farahmand B, Shokrzadeh M. Demographic characteristics and functional performance of the kidneys and hearts of patients with acute tramadol toxicity. Drug Res. 2018;69:207–210.
   PubMed Web of Science ®Google Scholar
• Stassinos GL, Gonzales L, Klein-Schwartz W. Characterizing the toxicity and dose-effect profile of tramadol ingestions in children. Pediatr Emerg Care. 2017;35:117–120.
   Web of Science ®Google Scholar
• Wu W, McKown L, Liao S. Metabolism of the analgesic drug ULTRAM®(tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica. 2002;32(5):411–425. doi:10.1080/0049825011011323012065063
   PubMed Web of Science ®Google Scholar
• Grond S, Meuser T, Uragg H, Stahlberg HJ, Lehmann KA. Serum concentrations of tramadol enantiomers during patient-controlled analgesia. Br J Clin Pharmacol. 1999;48(2):254–257.10417506
   PubMed Web of Science ®Google Scholar
• Dong H, Lu S-J, Zhang R, Liu D-D, Zhang Y-Z, Song C-Y. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients. Eur J Clin Pharmacol. 2015;71(6):681–686. doi:10.1007/s00228-015-1857-425948472
   PubMed Web of Science ®Google Scholar
• Li Q, Wang R, Guo Y, Wen S, Xu L, Wang S. Relationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteers. J Clin Pharm Ther. 2010;35(2):239–247. doi:10.1111/j.1365-2710.2009.01102.x20456744
   PubMed Web of Science ®Google Scholar
• Yu H, Hong S, Jeong CH, Bae JW, Lee S. Development of a linear dual column HPLC-MS/MS method and clinical genetic evaluation for tramadol and its phase I and II metabolites in oral fluid. Arch Pharm Res. 2018;41(3):288–298. doi:10.1007/s12272-017-0993-z29196917
   PubMed Web of Science ®Google Scholar
• Yu H, Choi M, Jang JH, et al. Development of a column-switching LC-MS/MS method of tramadol and its metabolites in hair and application to a pharmacogenetic study. Arch Pharm Res. 2018;41(5):554–563. doi:10.1007/s12272-018-1013-729524157
   PubMed Web of Science ®Google Scholar
• Byeon JY, Kim YH, Lee CM, et al. CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res. 2018;41(9):921–930. doi:10.1007/s12272-018-1075-630191460
   PubMed Web of Science ®Google Scholar
• Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol. 2011;164(2b):433–443. doi:10.1111/j.1476-5381.2011.01385.x21449914
   PubMed Web of Science ®Google Scholar
• Beal S, Sheiner L. NONMEM User Guides.  San Francisco, CA: NONMEM Project Group; 1998.
   Google Scholar
• Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64.10195646
   PubMed Web of Science ®Google Scholar
• Bressolle F, Rochette A, Khier S, Dadure C, Ouaki J, Capdevila X. Population pharmacokinetics of the two enantiomers of tramadol and O-demethyl tramadol after surgery in children. Br J Anaesth. 2009;102(3):390–399. doi:10.1093/bja/aen40519189983
   PubMed Web of Science ®Google Scholar
• Salman S, Sy SK, Ilett KF, Page-Sharp M, Paech MJ. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. Eur J Clin Pharmacol. 2011;67(9):899–908. doi:10.1007/s00228-011-1023-621394525
   PubMed Web of Science ®Google Scholar
• Murthy BP, Skee DM, Danyluk AP, Brett V, Vorsanger GJ, Moskovitz BL. Pharmacokinetic model and simulations of dose conversion from immediate-to extended-release tramadol. Curr Med Res Opin. 2007;23(2):275–284. doi:10.1185/030079906X16277317288681
   PubMed Web of Science ®Google Scholar
• Allegaert K, Holford N, Anderson BJ, et al. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. Clin Pharmacokinet. 2015;54(2):167–178. doi:10.1007/s40262-014-0191-925258277
   PubMed Web of Science ®Google Scholar
• Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist. 2006;11(2):126–135. doi:10.1634/theoncologist.11-2-12616476833
   PubMed Web of Science ®Google Scholar
• Grond S, Meuser T, Zech D, Hennig U, Lehmann KA. Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia. Pain. 1995;62(3):313–320.8657431
   PubMed Web of Science ®Google Scholar
• Skinner-Robertson S, Fradette C, Bouchard S, Mouksassi MS, Varin F. Pharmacokinetics of tramadol and O-desmethyltramadol enantiomers following administration of extended-release tablets to elderly and young subjects. Drugs Aging. 2015;32(12):1029–1043. doi:10.1007/s40266-015-0315-426508138
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Saadatmand AR, Lotsch J, Tegeder I, Stingl JC, Brockmoller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther. 2011;90(1):143–150. doi:10.1038/clpt.2011.5621562485
   PubMed Web of Science ®Google Scholar
• Stamer UM, Musshoff F, Stuber F, Brockmoller J, Steffens M, Tzvetkov MV. Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain. 2016;157(11):2467–2475. doi:10.1097/j.pain.000000000000066227541716
   PubMed Web of Science ®Google Scholar